Skip to content

Study · Randomized controlled trial · n = 737 · 2018

11 results

Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial.

Chen YH, Huang CN, Cho YM, Li P, Gu L, Wang F, Yang J, Wang WQ

Diabetes, obesity & metabolism5 Jun 2018Cited by 35 (Europe PMC)

PMID29708650 (opens in a new tab)PMCIDPMC6099453 (opens in a new tab)DOI10.1111/dom.13340 (opens in a new tab)PepBankPUB-29708650
Read at sourcePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In East-Asian patients with T2D, dulaglutide 1.5 mg was non-inferior and superior to glimepiride for HbA1c reduction.

    In plain wordsIn East-Asian patients with T2D, dulaglutide 1.5 mg reduced HbA1c more than glimepiride.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c change
    Study

    n: not reported in source

    Comparator
    Glimepiride
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg weekly · 26 weeksAs given in this study (human).

    Measurements

    HbA1c least squares mean difference vs glimepiride
    −0.58%
    dulaglutide 1.5 mg, week 26
    95% CI
    −0.76 to −0.39%
    dulaglutide 1.5 mg, week 26
    HbA1c least squares mean difference vs glimepiride
    −6.34 mmol/mol
    dulaglutide 1.5 mg, week 26
    95% CI
    −8.31 to −4.26 mmol/mol
    dulaglutide 1.5 mg, week 26

    Source sentences

    Summary
    At week 26, both doses of dulaglutide were non-inferior and also superior to glimepiride for HbA1c reduction from baseline with a least squares mean difference of -6.34 mmol/mol (95% confidence interval [CI] -8.31, -4.26) or -0.58% (95% CI -0.76, -0.39) for dulaglutide 1.5 mg
    3 context sentences
    Summary · context
    In this phase III, multinational, multicentre, double-blind, randomized, parallel-arm, 26-week study, patients with inadequate glycaemic control were randomized 1:1:1 to once-weekly dulaglutide 1.5 or 0.75 mg or daily glimepiride (1-3 mg/d).
    Summary · context
    The primary endpoint was assessment of the non-inferiority of dulaglutide (1.5 mg), as measured by change in glycated haemoglobin (HbA1c), compared with glimepiride using a 0.4% non-inferiority margin.
    Summary · context
    A total of 737 patients were randomized (dulaglutide 1.5 mg, n = 244; dulaglutide 0.75 mg, n = 248; glimepiride, n = 245).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In East-Asian patients with T2D, dulaglutide decreased body weight compared with glimepiride.

    In plain wordsIn East-Asian patients with T2D, dulaglutide decreased body weight compared with glimepiride.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseBody weight
    Study

    n = 737

    Comparator
    Glimepiride
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.5 mg or 0.75 mg once weekly · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    The mean body weight decreased (P < .005) and total hypoglycaemia rates were lower (P < .001) in the dulaglutide groups compared with the glimepiride group.
    1 context sentence
    Summary · context
    In this phase III, multinational, multicentre, double-blind, randomized, parallel-arm, 26-week study, patients with inadequate glycaemic control were randomized 1:1:1 to once-weekly dulaglutide 1.5 or 0.75 mg or daily glimepiride (1-3 mg/d).
  3. 03HumanRandomized controlled trialSafety outcome

    In East-Asian patients with T2D, dulaglutide had lower total hypoglycaemia rates than glimepiride.

    In plain wordsIn East-Asian patients with T2D, dulaglutide had lower low-blood-sugar rates than glimepiride.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseTotal hypoglycaemia
    Study

    n = 737

    Comparator
    Glimepiride
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    1.5 mg or 0.75 mg once weekly · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    The mean body weight decreased (P < .005) and total hypoglycaemia rates were lower (P < .001) in the dulaglutide groups compared with the glimepiride group.
    1 context sentence
    Summary · context
    In this phase III, multinational, multicentre, double-blind, randomized, parallel-arm, 26-week study, patients with inadequate glycaemic control were randomized 1:1:1 to once-weekly dulaglutide 1.5 or 0.75 mg or daily glimepiride (1-3 mg/d).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In East-Asian patients with T2D, dulaglutide 0.75 mg was non-inferior and superior to glimepiride for HbA1c reduction.

    In plain wordsIn East-Asian patients with T2D, dulaglutide 0.75 mg reduced HbA1c more than glimepiride.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c change
    Study

    n: not reported in source

    Comparator
    Glimepiride
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.75 mg weekly · 26 weeksAs given in this study (human).

    Measurements

    HbA1c least squares mean difference vs glimepiride
    −0.32%
    dulaglutide 0.75 mg, week 26
    95% CI
    −0.5 to −0.13%
    dulaglutide 0.75 mg, week 26
    HbA1c least squares mean difference vs glimepiride
    −3.5 mmol/mol
    dulaglutide 0.75 mg, week 26
    95% CI
    −5.47 to −1.42 mmol/mol
    dulaglutide 0.75 mg, week 26

    Source sentences

    Summary
    and -3.50 mmol/mol (95% CI -5.47, -1.42) or -0.32% (95% CI -0.50, -0.13) for dulaglutide 0.75 mg (P < .001).
    2 context sentences
    Summary · context
    At week 26, both doses of dulaglutide were non-inferior and also superior to glimepiride for HbA1c reduction from baseline
    Summary · context
    In this phase III, multinational, multicentre, double-blind, randomized, parallel-arm, 26-week study, patients with inadequate glycaemic control were randomized 1:1:1 to once-weekly dulaglutide 1.5 or 0.75 mg or daily glimepiride (1-3 mg/d).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In East-Asian patients with T2D, more patients on dulaglutide 1.5 mg than on glimepiride reached the HbA1c target of <7.0% at week 26 (74.1% vs 57.4%).

    In plain wordsIn East-Asian patients with T2D, more patients on dulaglutide 1.5 mg than on glimepiride reached the HbA1c target of below 7.0%.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseHbA1c below 7%
    Study

    n: not reported in source

    Comparator
    Glimepiride
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg weekly · 26 weeksAs given in this study (human).

    Measurements

    Target attainment
    74.1%
    dulaglutide 1.5 mg
    Target attainment
    57.4%
    glimepiride

    Source sentences

    Summary
    A greater proportion of patients in the dulaglutide 1.5 mg group achieved the HbA1c target of <53 mmol/mol (<7.0%) compared with the glimepiride group (74.1% vs 57.4%; P < .001).
    1 context sentence
    Summary · context
    In this phase III, multinational, multicentre, double-blind, randomized, parallel-arm, 26-week study, patients with inadequate glycaemic control were randomized 1:1:1 to once-weekly dulaglutide 1.5 or 0.75 mg or daily glimepiride (1-3 mg/d).
  6. 06HumanRandomized controlled trialSafety outcome

    In East-Asian patients with T2D, diarrhoea was a common drug-related adverse event in both dulaglutide groups.

    In plain wordsIn East-Asian patients with T2D, diarrhoea was a common drug-related adverse event in both dulaglutide groups.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableDiarrhoea
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.5 mg or 0.75 mg once weekly · 26 weeksAs given in this study (human).

    Measurements

    Patients with drug-related adverse event
    ≥ 5%
    each dulaglutide group, among the most common events

    Source sentences

    Summary
    The most common drug-related adverse events in both dulaglutide groups (≥5% of patients) included diarrhoea, nausea, increased lipase, decreased appetite, abdominal distension and vomiting.
    1 context sentence
    Summary · context
    In this phase III, multinational, multicentre, double-blind, randomized, parallel-arm, 26-week study, patients with inadequate glycaemic control were randomized 1:1:1 to once-weekly dulaglutide 1.5 or 0.75 mg or daily glimepiride (1-3 mg/d).
  7. 07HumanRandomized controlled trialSafety outcome

    In East-Asian patients with T2D, nausea was a common drug-related adverse event in both dulaglutide groups.

    In plain wordsIn East-Asian patients with T2D, nausea was a common drug-related adverse event in both dulaglutide groups.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableNausea
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.5 mg or 0.75 mg once weekly · 26 weeksAs given in this study (human).

    Measurements

    Patients with drug-related adverse event
    ≥ 5%
    each dulaglutide group, among the most common events

    Source sentences

    Summary
    The most common drug-related adverse events in both dulaglutide groups (≥5% of patients) included diarrhoea, nausea, increased lipase, decreased appetite, abdominal distension and vomiting.
    1 context sentence
    Summary · context
    In this phase III, multinational, multicentre, double-blind, randomized, parallel-arm, 26-week study, patients with inadequate glycaemic control were randomized 1:1:1 to once-weekly dulaglutide 1.5 or 0.75 mg or daily glimepiride (1-3 mg/d).
  8. 08HumanRandomized controlled trialSafety outcome

    In East-Asian patients with T2D, increased lipase was a common drug-related adverse event in both dulaglutide groups.

    In plain wordsIn East-Asian patients with T2D, increased lipase was a common drug-related adverse event in both dulaglutide groups.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableIncreased lipase
    Study

    n: not reported in source

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    1.5 mg or 0.75 mg once weekly · 26 weeksAs given in this study (human).

    Measurements

    Patients with drug-related adverse event
    ≥ 5%
    each dulaglutide group, among the most common events

    Source sentences

    Summary
    The most common drug-related adverse events in both dulaglutide groups (≥5% of patients) included diarrhoea, nausea, increased lipase, decreased appetite, abdominal distension and vomiting.
    1 context sentence
    Summary · context
    In this phase III, multinational, multicentre, double-blind, randomized, parallel-arm, 26-week study, patients with inadequate glycaemic control were randomized 1:1:1 to once-weekly dulaglutide 1.5 or 0.75 mg or daily glimepiride (1-3 mg/d).
  9. 09HumanRandomized controlled trialSafety outcome

    In East-Asian patients with T2D, decreased appetite was a common drug-related adverse event in both dulaglutide groups.

    In plain wordsIn East-Asian patients with T2D, decreased appetite was a common drug-related adverse event in both dulaglutide groups.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableDecreased appetite
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    1.5 mg or 0.75 mg once weekly · 26 weeksAs given in this study (human).

    Measurements

    Patients with drug-related adverse event
    ≥ 5%
    each dulaglutide group, among the most common events

    Source sentences

    Summary
    The most common drug-related adverse events in both dulaglutide groups (≥5% of patients) included diarrhoea, nausea, increased lipase, decreased appetite, abdominal distension and vomiting.
    1 context sentence
    Summary · context
    In this phase III, multinational, multicentre, double-blind, randomized, parallel-arm, 26-week study, patients with inadequate glycaemic control were randomized 1:1:1 to once-weekly dulaglutide 1.5 or 0.75 mg or daily glimepiride (1-3 mg/d).
  10. 10HumanRandomized controlled trialSafety outcome

    In East-Asian patients with T2D, abdominal distension was a common drug-related adverse event in both dulaglutide groups.

    In plain wordsIn East-Asian patients with T2D, abdominal distension was a common drug-related adverse event in both dulaglutide groups.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableAbdominal distension
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.5 mg or 0.75 mg once weekly · 26 weeksAs given in this study (human).

    Measurements

    Patients with drug-related adverse event
    ≥ 5%
    each dulaglutide group, among the most common events

    Source sentences

    Summary
    The most common drug-related adverse events in both dulaglutide groups (≥5% of patients) included diarrhoea, nausea, increased lipase, decreased appetite, abdominal distension and vomiting.
    1 context sentence
    Summary · context
    In this phase III, multinational, multicentre, double-blind, randomized, parallel-arm, 26-week study, patients with inadequate glycaemic control were randomized 1:1:1 to once-weekly dulaglutide 1.5 or 0.75 mg or daily glimepiride (1-3 mg/d).
  11. 11HumanRandomized controlled trialSafety outcome

    In East-Asian patients with T2D, vomiting was a common drug-related adverse event in both dulaglutide groups.

    In plain wordsIn East-Asian patients with T2D, vomiting was a common drug-related adverse event in both dulaglutide groups.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableVomiting
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.5 mg or 0.75 mg once weekly · 26 weeksAs given in this study (human).

    Measurements

    Patients with drug-related adverse event
    ≥ 5%
    each dulaglutide group, among the most common events

    Source sentences

    Summary
    The most common drug-related adverse events in both dulaglutide groups (≥5% of patients) included diarrhoea, nausea, increased lipase, decreased appetite, abdominal distension and vomiting.
    1 context sentence
    Summary · context
    In this phase III, multinational, multicentre, double-blind, randomized, parallel-arm, 26-week study, patients with inadequate glycaemic control were randomized 1:1:1 to once-weekly dulaglutide 1.5 or 0.75 mg or daily glimepiride (1-3 mg/d).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.